Brief: Gilead Sciences And Kymera Therapeutics Enter Into Exclusive Option And License Agreement
25/06/2025 12:04
June 25 (Reuters) - Gilead Sciences Inc GILD.O: GILEAD SCIENCES AND KYMERA THERAPEUTICS ENTER INTO EXCLUSIVE OPTION AND LICENSE AGREEMENT TO DEVELOP NOVEL ORAL MOLECULAR GLUE CDK2 DEGRADERS GILEAD SCIENCES INC - KYMERA ELIGIBLE TO RECEIVE UP TO $750 MILLION IN PAYMENTS GILEAD SCIENCES INC - DEAL EXPECTED TO REDUCE GILEAD'S 2025 EPS BY $0.02-$0.03 Source text: ID:nBw99Cwya Further company coverage: GILD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kymera Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Adobe, Dell Technologies, Zscaler
Kymera Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Kymera Therapeutics Q2 collaboration revenue more than doubles, beats estimates
Brief: Kymera Therapeutics Q2 EPS USD -0.62
Brief: Kymera Therapeutics Appoints Terence Rooney, MD, As Chief Medical Officer